GlassScriptPhysician profile
Anna Urazov
NPI 1427580208
$5,307.80
in general payments reported to CMS, 2019-2025
31 companies · $2,892 in 2025
The $2,892 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.00 · 2023: $674 · 2024: $1,692 · 2025: $2,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,324 · Education: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,323.94 |
| Education | $933.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $570.45 | 2023-2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $568.17 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astellas Pharma US INC | $544.54 | 2023-2025 | Xtandi, Vyloy |
| Janssen Biotech, INC. | $461.57 | 2024-2025 | Darzalex, Tecvayli, Erleada |
| Seagen INC. | $443.68 | 2023-2025 | Adcetris, Tukysa |
| Exelixis INC. | $385.00 | 2024-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $328.42 | 2025 | Imfinzi, Enhertu, Tagrisso |
| Eisai INC. | $296.70 | 2024-2025 | Lenvima |
| Takeda Pharmaceuticals U.S.A., INC. | $252.70 | 2024-2025 | Ninlaro, Fruzaqla, Vpriv |
| Incyte Corporation | $189.22 | 2024-2025 | Monjuvi, Zynyz, Pemazyre |
| Novartis Pharmaceuticals Corporation | $180.41 | 2024-2025 | |
| Gilead Sciences, INC. | $161.85 | 2022-2023 | Trodelvy |
| Lilly USA, LLC | $133.83 | 2024-2025 | Verzenio, Retevmo, Jaypirca |
| Pfizer INC. | $115.19 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $86.90 | 2024-2025 | Pyrukynd |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $73.94 | 2024 | |
| Deciphera Pharmaceuticals INC. | $67.76 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Taiho Oncology, INC. | $66.52 | 2025 | Inqovi, Lonsurf |
| Accord Healthcare, INC. | $59.27 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.69 | 2025 | |
| Genzyme Corporation | $34.89 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.46 | 2025 | |
| Genmab U.S., INC. | $29.98 | 2023 | Tivdak |
| Celgene Corporation | $29.34 | 2025 | Reblozyl |
| Sumitomo Pharma America, INC. | $27.14 | 2024 | Orgovyx |
| Glaxosmithkline, LLC. | $24.68 | 2025 | Jemperli, Zejula |
| Regeneron Healthcare Solutions, INC. | $24.35 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $24.07 | 2025 | |
| Kyowa Kirin, INC. | $21.99 | 2024 | Poteligeo |
| Syndax Pharmaceuticals, INC. | $17.04 | 2025 | Revuforj |
| E.R. Squibb & Sons, L.L.C. | $14.05 | 2023 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Urazov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.